We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by ...
Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...
PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but ...
Director Antal Rohit Desai of PROCEPT BioRobotics Corp (NASDAQ:PRCT) reported purchasing shares of common stock in multiple transactions between March 5 and March 9, 2026. The total value of these ...
Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...
Q4 2025 earnings call recap: revenue, procedure growth, 2026 guidance, margin drivers & risks from sales changes—read now.
PROCEPT BioRobotics ( (PRCT)) has shared an update. On March 5, 2026, PROCEPT BioRobotics expanded its board of directors from eight to nine members and appointed former Shockwave Medical Chief ...
Fintel reports that on March 6, 2026, Baird initiated coverage of PROCEPT BioRobotics (NasdaqGM:PRCT) with a Neutral recommendation. Analyst Price Forecast Suggests 122.20% Upside As of February 25, ...
Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems ...
PROCEPT BioRobotics Corp. PRCT shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance. Performance Metrics In its ...
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...
Taking a look inside the human body has never been easier — just swallow a camera in the shape of a pill. However, what is not quite as easy is retrieving a piece of whatever you’re viewing. This is ...